Oncolytics biotech® announces receipt of nasdaq notification letter regarding minimum bid price deficiency

San diego and calgary, ab , feb. 14, 2025 /prnewswire/ -- oncolytics biotech® inc. (nasdaq: oncy) (tsx: onc), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "notice") from the listing qualifications department of the nasdaq stock market llc ("nasdaq") on february 13, 2025 indicating that the company is not currently in compliance with the minimum bid price requirement set forth in nasdaq's listing rules for continued listing on the nasdaq capital market, as the closing bid price for the company's ordinary shares listed on the nasdaq capital market was below $1.00 per share for 30 consecutive business days. nasdaq listing rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and nasdaq listing rule 5810(c)(3)(a) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
NDAQ Ratings Summary
NDAQ Quant Ranking